Cargando…
Silencing of AURKA augments the antitumor efficacy of the AURKA inhibitor MLN8237 on neuroblastoma cells
BACKGROUND: Aurora kinase A (AURKA) has been implicated in the regulation of cell cycle progression, mitosis and a key number of oncogenic signaling pathways in various malignancies including neuroblastoma. Small molecule inhibitors of AURKA have shown potential, but still not as good as expected ef...
Autores principales: | Yang, Yan, Ding, Lili, Zhou, Qi, Fen, Li, Cao, Yuhua, Sun, Junjie, Zhou, Xuefeng, Liu, Aiguo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947931/ https://www.ncbi.nlm.nih.gov/pubmed/31920463 http://dx.doi.org/10.1186/s12935-019-1072-y |
Ejemplares similares
-
MicroRNA expression profiles in extracellular vesicles and intracellular of AURKA inhibitor-induced senescent neuroblastoma cells
por: Zhou, Xuefeng, et al.
Publicado: (2022) -
MLN8054 and Alisertib (MLN8237): Discovery of Selective
Oral Aurora A Inhibitors
por: Sells, Todd B., et al.
Publicado: (2015) -
A Novel Aurora-A Inhibitor (MLN8237) Synergistically Enhances the Antitumor Activity of Sorafenib in Hepatocellular Carcinoma
por: Zhang, Kai, et al.
Publicado: (2018) -
Aurora kinase A (AURKA) promotes the progression and imatinib resistance of advanced gastrointestinal stromal tumors
por: Cheng, Xiaobin, et al.
Publicado: (2021) -
AURKA inhibition mimics BRCAness
por: Hirst, Jeff, et al.
Publicado: (2017)